Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Viking Therapeutics, Inc.NASDAQ: VKTX
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow growth accelerates
Q2 FY2026 financing cash flow of $23.59M rose 4552.1% year over year, ahead of the +2441.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 95.3% from the prior quarter. Over 3 fiscal years it compounded at +163.8% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +4552.1% holds above the trailing-twelve-month pace of +2441.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 76.44M USD
- Year-over-year change
- -87.5%
- 4-year CAGR
- +82.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 76.44M | -87.5% |
| FY2024 | 2024-12-31 | 612.46M | +125.7% |
| FY2023 | 2023-12-31 | 271.38M | +6418.8% |
| FY2022 | 2022-12-31 | 4.16M | -39.5% |
| FY2021 | 2021-12-31 | 6.88M | — |
Financing Cash Flow vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 financing cash flow of $111.25M is the 4th largest of the 7 companies compared; the peer median is $135.37M.
- Its year-over-year change of +2441.0% is the 2nd highest of 6, against a peer median of +0.4%.
- Over three fiscal years its annual growth of +163.8% compares with a peer median of -6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | FY2025 | $598.66M | — | — | — |
| LTM Jun 2026 | $251.04M | +567.4% | -6.5% | 19.6% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $189.81M | +0.4% | +60.3% | — |
| LTM Jun 2026 | $111.25M | +2441.0% | +163.8% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $80.93M | -73.5% | -61.7% | 84.1% |
| LTM Mar 2026 | $77.44M | +3044.2% | +76.9% | 210.2% | |
| LTM Jun 2026 | $41.68M | -91.1% | -57.8% | 585.3% | |
| Peer median (excluding VKTX) | $135.37M | +0.4% | -6.5% | 147.1% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 8.67M | 16.75M | 29.71M | 40.82M |
| Change in Working Capital | (2.93M) | 10.19M | 3.55M | 9.36M | 48.98M |
| Accounts Receivables | 1.18M | 614K | 321K | 1.2M | 5.08M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.54M) | 7.09M | (1.02M) | 2.3M | 43.44M |
| Other Working Capital | (1.56M) | 2.49M | 4.25M | 5.86M | 464K |
| Other Non-Cash Items | 3.94M | 1.32M | (8.07M) | (17.25M) | (9.27M) |
| Operating Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (168.02M) | (121.43M) | (478.3M) | (1.11B) | (418.04M) |
| Sales of Investments | 205.98M | 176.18M | 299.22M | 560M | 759.43M |
| Other Investing Activities | 0 | 54.75K | 0 | 0 | 0 |
| Investing Cash Flow | 37.96M | 54.75M | (179.09M) | (553.37M) | 341.39M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 7.59M | 0 | 269.76M | 597.09M | 2.49M |
| Common Stock Repurchased | 0 | (6.8M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (707K) | 12.49M | 1.62M | 15.37M | 73.95M |
| Financing Cash Flow | 6.88M | 4.16M | 271.38M | 612.46M | 76.44M |
| Effect of Forex Changes | 0 | (258K) | (30K) | (148K) | (8K) |
| Net Change in Cash | (2.75M) | 10.26M | 18.88M | (28.84M) | 139.13M |
| Free Cash Flow | (47.59M) | (48.4M) | (73.38M) | (87.79M) | (278.69M) |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.